Mesoblast (MEOBF) Cash & Equivalents (2014 - 2026)

Mesoblast has disclosed Cash & Equivalents across 13 years of filings, most recently posting $102.9 million for Q2 2026.

• In Q2 2026, Cash & Equivalents fell 36.3% year-over-year to $102.9 million; the TTM figure through Jun 2026 stood at $102.9 million (down 36.3% YoY), while the FY2026 annual figure was $102.9 million, down 36.3% from the prior year.
• Cash & Equivalents came in at $102.9 million for Q2 2026 at Mesoblast, down from $130.0 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $161.6 million in Q2 2025 to a low of $38.0 million in Q4 2024.
• Average Cash & Equivalents over 5 years is $82.0 million, with a median of $74.0 million recorded in 2022.
• Year-over-year, Cash & Equivalents plunged 55.84% in 2022 and surged 241.78% in 2025.
• Over 5 years, Cash & Equivalents stood at $67.6 million in 2022, then gained by 14.69% to $77.6 million in 2023, then sank by 50.96% to $38.0 million in 2024, then surged by 241.78% to $130.0 million in 2025, then fell by 20.82% to $102.9 million in 2026.
• Per Business Quant data, the three most recent Cash & Equivalents figures were $102.9 million in Q2 2026, $130.0 million in Q4 2025, and $161.6 million in Q2 2025.